NASDAQ: HSCSHeart Test Laboratories Inc Stock
$4.25-0.22 (-4.92%)
Updated Dec 6, 2024
HSCS Price
$4.25
Fair Value Price
N/A
Market Cap
$3.87M
52 Week Low
$2.36
52 Week High
$19.14
P/E
-0.2x
P/B
0.65x
P/S
160.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.60k
Earnings
-$7.29M
Gross Margin
67.3%
Operating Margin
-37,363.96%
Profit Margin
-39,193.8%
Debt to Equity
0.38
Operating Cash Flow
-$7M
Beta
0.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HSCS Overview
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HSCS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Value
B
Growth
F
Momentum
C
Sentiment
F
Safety
D
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important HSCS news, forecast changes, insider trades & much more!
HSCS News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HSCS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HSCS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HSCS is good value based on its book value relative to its share price (0.65x), compared to the US Medical Devices industry average (4.05x)
P/B vs Industry Valuation
HSCS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HSCS due diligence checks available for Premium users.
Valuation
HSCS fair value
Fair Value of HSCS stock based on Discounted Cash Flow (DCF)
Price
$4.25
Fair Value
$6.42
Undervalued by
33.82%
HSCS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HSCS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
36.83x
Market
29.86x
HSCS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.65x
Industry
4.05x
HSCS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HSCS's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.1M
Profit Margin
0%
HSCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HSCS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.2M
Liabilities
$2.3M
Debt to equity
0.38
HSCS's short-term assets ($6.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSCS's short-term assets ($6.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSCS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$833.0
Financing
$551.7k
HSCS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HSCS vs Medical Device Stocks
Heart Test Laboratories Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.